Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ownership Breakdown Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.


Top institutional share ownership of Aurinia Pharmaceuticals Inc

Name Shares Shares % change Value Value % change
BlackRock Inc. 7,811,743 327.5% $78,507 247.0%
Fmr Llc 4,889,323 -24.2% $49,139 -38.5%
NEA Management Company, LLC 3,969,834 0.0% $39,897 -18.8%
IWM - iShares Russell 2000 ETF 3,046,283 $30,615
Morgan Stanley 2,890,904 -5.0% $29,054 -22.9%
Bellevue Group AG 2,671,413 11.0% $26,848 -9.9%
State Street Corp 2,387,862 355.5% $23,998 269.8%
FAGAX - Fidelity Advisor Growth Opportunities Fund Class A 1,825,600 23.5% $20,593 13.3%
Susquehanna International Group, Llp 1,716,967 -10.7% $17,256 -27.5%
Vanguard Group Inc 1,168,957 120.5% $11,749 79.1%

Top institutional buyers of Aurinia Pharmaceuticals Inc

Name Shares % change Value % change Shares Value
Geode Capital Management, Llc 938.0% 743.1% 1,163,563 $11,694
Northern Trust Corp 897.3% 709.8% 1,019,317 $10,244
State Street Corp 355.5% 269.8% 2,387,862 $23,998
BlackRock Inc. 327.5% 247.0% 7,811,743 $78,507
Barclays Plc 134.6% 90.5% 1,041,054 $10,464
Goldman Sachs Group Inc 132.6% 88.9% 720,434 $7,241
Vanguard Group Inc 120.5% 79.1% 1,168,957 $11,749
FAGAX - Fidelity Advisor Growth Opportunities Fund Class A 23.5% 13.3% 1,825,600 $20,593
Citigroup Inc 12.4% -8.7% 861,737 $8,660
Bellevue Group AG 11.0% -9.9% 2,671,413 $26,848

Top institutional sellers of Aurinia Pharmaceuticals Inc

Name Shares % change Value % change Shares Value
FBTAX - Fidelity Advisor Biotechnology Fund Class A -31.0% -45.1% 678,900 $5,553
Stifel Financial Corp -26.5% -40.3% 1,041,537 $10,467
Citadel Advisors Llc -24.4% -38.6% 869,244 $8,736
Fmr Llc -24.2% -38.5% 4,889,323 $49,139
Susquehanna International Group, Llp -10.7% -27.5% 1,716,967 $17,256
Morgan Stanley -5.0% -22.9% 2,890,904 $29,054

Information provided by Fintel.io